Daily Archives: May 20, 2022

Studies in worms, flies, rodents, and monkeys have demonstrated that diets that severely restrict total calorie intake, while providing all the essential nutrients, extend average lifespan.

The research shows that in all these organisms, food shortages trigger physiological changes that promote longevity and delay the onset of age-related disease.

Calorie-restricted diets in humans, which involve reducing average calorie intake by around a third, may also extend human lifespan, though hard evidence is currently lacking.

Animal studies have revealed that timing of calorie restriction can have an effect due to the circadian system, which controls daily cycles of physiology, metabolism, and behaviors such as eating. This has also been linked to aging.

This led researchers at the University of Texas (UT) Southwestern Medical Center in Dallas, TX, to investigate whether the timing of meals contributes to the life-extending effects of calorie restriction.

Numerous studies have shown that calorie restriction increases the average lifespan of mice. But most of this research has involved scientists feeding calorie-restricted diets to laboratory mice during the day.

Unlike humans, mice are nocturnal, which means they have evolved to feed at night.

So for their study, the scientists used automatic feeders to ensure that some of the mice ate only during the night.

To determine whether the timing of meals had an effect on lifespan independently of calorie restriction and fasting they split the animals into 6 groups.

In one group, which served as a control, the animals could eat ad libitum (as much as they wanted, whenever they wanted).

The remaining 5 groups ate calorie-restricted diets (3040% fewer calories) with the same total calorie intake but different feeding schedules.

Control mice that ate ad libitum had a median lifespan of 800 days, whereas mice on a calorie-restricted diet with food available around the clock lived 875 days, or 10% longer.

Mice on the calorie-restricted diet that ate only during the day (the inactive phase of their circadian cycle) and fasted for 12 hours overnight lived 959 days. In other words, they lived almost 20% longer than the controls.

But calorie-restricted mice that only ate during their active phase, then fasted for the remaining 12 hours, lived the longest. These animals clocked up an average 1,068 days of lifespan, which was nearly 35% longer than the control animals.

The scientists have reported their findings in Science.

We have discovered a new facet to caloric restriction that dramatically extends lifespan in our lab animals, says senior author Dr. Joseph Takahashi, Howard Hughes Medical Institute Investigator and chair of neuroscience at UT Southwestern Medical Center.

If these findings hold true in people, we might want to rethink whether we really want that midnight snack, he adds.

They also found that calorie-restricted diets improved the animals regulation of glucose levels and insulin sensitivity, but the improvements were greatest for mice that ate only at night (their active phase).

This suggests that the mice were healthier and aged more slowly, Dr. Takahashi told Medical News Today.

The researchers found that, in all the mice, aging increased the activity of genes involved in inflammation and decreased the activity of genes involved in metabolism and circadian rhythms.

Calorie restriction slowed down these age-related changes, but mice that only ate a night reaped the greatest benefits.

Since aging can be considered a progressive ramping up of inflammation, [calorie restriction] is also delaying this age-related increase in inflammation, which is also consistent with delaying the aging process, said Dr. Takahashi.

The authors note some limitations of their study.

In particular, they write that sleep disruption in the mice that ate during the day (during their inactive phase) may have contributed to their shorter lifespan.

In addition, all the mice in the study were male. The authors write that in females, ovarian hormones may provide some protection against disruptions in circadian rhythms.

As with all research that involves animal models, the study may not translate well to humans.

If the findings do apply to humans, which have the opposite active phase to mice, the scientists suggest that eating early in the evening is best for healthy aging.

One day it may even be possible to develop drugs that target circadian genes or the proteins that they make, in order to mimic the anti-aging benefits of eating only during the active phase.

[W]e are working on this idea and searching for drugs that can enhance circadian alignment, said Dr. Takahashi. Fingers crossed!

Eating late at night interferes with the bodys ability to keep blood sugar levels within a healthy range.

A recent study found this was particularly true for people with a particular variation of the gene for the melatonin receptor.

Melatonin is a hormone that helps to govern the sleep-wake cycle. As its levels increase in the evening, this not only triggers sleepiness but also impairs insulin secretion.

As a result, the body has more difficulty controlling blood sugar levels after meals close to bedtime.

Since many people opt for carbohydrate-rich snacks in late evenings, such as chips, cookies, candy, or popcorn, these snacks are more likely to impair blood sugar control and increase ones risk for prediabetes and diabetes, said Mariam Eid, R.D., L.D., a dietitian and founder of A Happy AOneC, which advises teens and young adults recently diagnosed with prediabetes.

Therefore, consuming carbohydrate-rich meals and snacks earlier in the day promotes better blood sugar balance and supports the prevention of prediabetes and diabetes, she told MNT.

The rest is here:
Eating earlier in the evening may have anti-aging benefits - Medical News Today

Once upon a time, I had a pretty awkward and comical date in Santa Monica. I was new-ish to Los Angeles and decided to try out a dating site that was famous for its robust matching algorithms. However, on this particular evening on Pico Boulevard, their matching science was, well, not so robust.

I probably should have known something was awry when the handsome maitre d' wished me "good luck" in a distinct, you're-gonna-need-it kind of tone before taking me to the table where my date was already seated.

In lieu of a warm salutation, my date stood up, scanned me from toes to head (yes, in that particular order), and proclaimed with some audible disappointment, "You're taller than yourdating appprofile said." I replied, "It's nice to meet you too" like any gracious Southern lady would, and proceeded to sit my tall self down. (I'm actually a not-so-tall 5-feet-6-inches, but as my dating profile clearly stated, "I like to wear heels," so you know, do the math.)

The rest of that date could inspire a Saturday Night Live skit, but allow me to cut to the nutrition-relevant chase (since this articleisabout nutrition principles and foodstuffs for a long and healthy life, I promise).

Originally posted here:
You Have Control Over Your Healthspan: A PhD's Go-To Nutrients For Longevity - mindbodygreen.com

Anderson, South Carolina--(Newsfile Corp. - May 18, 2022) - JZZ Technologies Inc. (OTC Pink: JZZI), a diversified technology company focused on digital media and strategic biotechnology acquisitions related to human life extension including human longevity ("JZZ" or the "Company"), is entering into a working relationship with North Brunswick, New Jersey-based DataBoss Inc. ("DataBoss") which is creating relationships with other anticipated entities to validate and enhance its proprietary marketing database of seniors for the purpose of licensing portions of the database to a number of Big Tech companies which are looking to expand their audience reach.

JZZ Technologies, Inc., through its subsidiary Active Lifestyle, has been validating the marketing value of its database of over 35 million seniors. DataBoss has advised JZZ that it has independently valued the database at more than $3 per individual record.

DataBoss, along with other entities with which it is creating relationships, will be assisting JZZ in licensing targeted portions of the database in blocks of several hundred thousand records per agreement to Big Tech companies over the coming quarters. JZZ anticipates that it will be generating revenues of approximately $1 million per month from the licensing agreements. As the database continues to be validated and additional seniors are added, JZZ anticipates substantial revenue growth generated from future licensing agreements.

DataBoss, a leading data and technology company, was founded by Neel Sawant who serves its current president and CEO.

Neel Sawant has over 30-years of International executive IT leadership experience. His expertise lies in identifying innovative, next generation products and solutions and undervalued companies with strategic synergies that can be leveraged for growth in a multi-billion-dollar market. His expertise lies in effectively combining culturally diverse subsidiaries and acquisitions with excellent business processes and strategy development skills.

Story continues

Mr. Sawant's approach is client centric, with the ability to initiate and grow profitable alliances with global vendors and suppliers. By applying this approach, he has successfully developed and sold a rollup corporation (Sii Group) which operated internationally. He presently focuses on M&A and helping companies list with major exchanges, such as at NASDAQ, which companies have an aggregate market cap which exceeds $10 billion. Companies that Mr. Sawant has been engaged with include AmpliTech Group. Inc, Coeptis Therapeutics, CB Scientific Inc., Gourmet Provisions International, Quantum Kore, Xeriant Aerospace, BlockQuarry, TGI Power, Ealixir Inc. and Shubh Network, among others.

Charles Cardona, JZZ's CEO, stated, "JZZ expects to announce new, significant gains in revenues, new strategic partnerships and new products in the coming months resulting from our relationship with DataBoss and Big Tech partners. We're also working on a number of investment initiatives to support our anticipated growth."

Neel Sawant, CEO of DataBoss, commented, "I am excited at the prospect of DataBoss helping monetize the proprietary ActiveLifestyle Media database owned by JZZ Technologies. I am confident we can maximize its values and immediately create new products for a broad range of companies. With our shared capabilities, I believe JZZ's database would help Big Tech companies increase their outreach to new clients."

About DataBoss Inc.

DataBoss Inc., with its unique combination of data-driven decision systems and experienced experts, identifies and facilitates investments in high-potential profit oriented yet responsible companies that provide value to society through sustainable technologies with applications in cleantech, health tech, and other emerging technologies. For more information, please visit Databoss.network.

About JZZ Technologies, Inc.

JZZ Technologies, Inc. is a diversified technology company engaged in the following three distinct business sectors: (i) its digital media business which includes online media and apps (activelifestylemedia.com), content creation, and digital marketing, targeted to active adults 55+, (ii) strategic biotechnology and bioscience related to Human Life Extension and (iii) Human Longevity that can be immediately leveraged to support improved quality of life for the senior population. For more information, please visit http://www.jzztechnologies.com.

Press Contact:JZZ Technologies, Inc.Charles Cardona, CEOccardona@jzztechnologies.com

DISCLAIMER and FORWARD-LOOKING STATEMENTS

Certain statements contained herein are "forward-looking" statements (as such term is defined in the Private Securities Litigation Reform Act of 1995). Because such statements include risks and uncertainties, actual results may differ materially from those expressed or implied by such forward-looking statements. This press release may contain certain forward-looking statements within the meaning of Section 27A of the Securities and Exchange Act of 1933, as amended, and Section 21E of the Securities and Exchange Act of 1934, as amended, and such Forward-Looking Statements are intended to be covered by the safe harbors created thereby. Investors are cautioned that all forward-looking statements involve risks and uncertainties. All statements other than statements of historical fact in this announcement are forward-looking statements, including but not limited to the viability of the Company's business plans, the effect of acquisitions on our profitability, the effectiveness, profitability, and the marketability of the Company's products; the Company's ability to protect its proprietary information; general economic and business conditions; and the volatility of the Company's operating results and financial condition. These forward-looking statements involve known and unknown risks and uncertainties and are based on current expectations, assumptions, estimates, and projections about the Company and the industry. The Company undertakes no obligation to update forward-looking statements to reflect subsequent occurring events or circumstances or to changes in its expectations, except as may be required by law. Although the Company believes that the expectations expressed in these forward-looking statements are reasonable, management cannot assure the public that their expectations will turn out to be correct. Investors are cautioned that actual results may differ materially from the anticipated results.

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/124442

See original here:
JZZ Technologies, Inc. Receives Significant Increase in Valuation of Its Proprietary Database of over 35 Million Seniors - Yahoo Finance

BERLIN, GERMANY / ACCESSWIRE / May 19, 2022 / The Forever Healthy Foundation is pleased to announce the worlds first Rejuvenation Startup Summit will be held October 14-15, 2022 in Berlin. The Rejuvenation Startup Summit is a vibrant networking event for rejuvenation startups, longevity investors, and translational researchers, and aims to accelerate the development of the rejuvenation biotech industry.

Startups will be able to connect with investors in the longevity space, present their approach, and get them interested in their work. Investors can meet the most promising rejuvenation startups from all over the world and get in touch with them straight away. Researchers with a startup itch can learn how to successfully break out of the lab and found or join a rejuvenation startup.

The summit brings together all those working on therapies that aim to vastly extend the healthy human lifespan. In addition to an exciting range of keynote speeches, presentations, and panels, the summit features an all-day startup forum for easy networking. Starting midday on Friday and finishing off on Saturday night with a big party, it offers ample opportunity to connect, learn and network with the most relevant players in the field.

The Rejuvenation Startup Summit is not only open to startups, investors, and translational scientists all interested members of the broader longevity movement, scientists from related fields, aspiring students, and the general media are welcome.

Learn more at: https://forever-healthy.org/summit

About Forever Healthy

Forever Healthy is Michael Greves humanitarian initiative with the mission of enabling people to vastly extend their healthy lifespan. Forever Healthys projects include evaluation of new rejuvenation therapies, evidenced-based curation of the worlds cutting-edge medical knowledge, funding translational research on the root causes of aging, and hosting the annual Undoing Aging Conference and the Rejuvenation Startup Summit. Greves venture capital firm, Kizoo, which provides mentoring, seed and follow-on financing for rejuvenation biotech startups, is also part of the initiative. To date, Kizoo has funded fourteen startups turning research on the root causes of aging into therapies for human application.

Learn more at https://www.forever-healthy.org

Media Contact for Forever Healthy

Frank Schueler, Chief Operating Officer[emailprotected]

SOURCE: Forever Healthy Foundation gGmbH

View source version on accesswire.com: https://www.accesswire.com/702009/Rejuvenation-Startup-Summit-premieres-October-14-15-2022-in-Berlin

View post:
Rejuvenation Startup Summit premieres October, 14-15, 2022 in Berlin - Digital Journal

Concept of a healthy female reproductive system.

The field of female reproductive longevity and inequality is getting more and more attention. In fact, it is one of the hottest areas of the emerging longevity biotechnology industry, and every venture firm in the field is either investing, incubating, or looking for projects in this area. Companies like BOLD Capital, Future Ventures, LongeVC, and iconic biotechnology investors including Bob Nelsen and Christian Angermayer, are all active and significant partners in this area of science. While females generally live longer than men, their reproductive period is limitedsomething that is often overlooked. A females peak reproductive years are between the late teens and late 20s. Fertility starts to decline by age 30, and this decline becomes more rapid once women reach the mid-30s. By 45, fertility declines so much that getting pregnant naturally is unlikely for most women. Likewise, women begin life with a fixed number of eggs in their ovaries, usually around one million. This number decreases as women age. Ovaries age faster than the rest of a womans bodyan understudied phenomenon of a neglected organ. None of us would be here without them. Yet surprisingly little is known about the avocado-shaped organ thats nestled inside half of all humans.

Functional decline in female fertility with age

The ovaries also influence a womans overall health and well-being. This includes how they age, since this organ tends to lose its function with age faster than any other tissue. This is called asynchronous aging, and its one reason why a womans fertility declines, and menopause strikes, while they are still relatively young.

In one of my previous articles, I wrote about Gameto, a biotechnology company that is translating the impact of ovarian aging to develop solutions to improve fertility and stop the impact of menopause on female health. Gametos co-founder and CEO Dina Radenkovic told me about her intention to redefine the narrative around female reproductive longevity and making it more around health and longevity. Gameto is building a platform for ovarian therapeutics to address menopause and improve assisted fertility. Dina told me she hopes it will make women suffer fewer health problems in their later lives. Neglecting the ovariesexcept for their crucial role in IVF treatmentshas been part of a general disregard for many aspects of womens health in the biomedical world.

What surprises me is this: If overall life expectancy is increasing, and it has consistently over the past decade, then shouldnt there be more focus on extending female reproductive life too? Without extending female reproductive life, we are worsening gender inequality in society.

Just two years ago, Nature published a major study out of Stanford University on the variability in rates of cellular aging in 17 major organs. These included the heart, kidney, and spleenbut not the ovaries, despite it being #1 among organs that rapidly age and are known to influence cellular aging in the rest of the body upon their decline.

Luckily, tides are turning, and female reproductive longevity and inequality are rapidly turning into the hottest research areas in longevity science and investment themes in longevity venture capital.

The official headshot of Maryanna Sayenko, co-founder of Future Ventures

I think womens reproductive longevity is becoming an interesting investment sector because its at the nexus of several important trends. Research in this space is finally getting the recognition and influx of talent that it so desperately needs, thanks in large part to efforts of people like Jennifer Garrison who have been championing the needs of the field. Second, investors are recognizing that addressing longevity without attending to womens reproductive longevity is a laughably incomplete picture. Finally, in the last few years incredible entrepreneurs are taking the risk and entering the space with scientifically credible companies, says Maryanna Saenko, a celebrity venture capitalist who co-pilots Future Ventures together with Steve Jurvetson. Saenko and Jurvetson recently backed Gameto and Cambrian Biosciences.

Dr. Daisy Robinton, scientist, model, entrepreneur, founder and CEO of Oviva Therapeutics

In 2020, molecular biologist Daisy Robinton, while working with a biotechnology company to help develop a potential treatment for COVID-19, was told by male colleagues on a Zoom call to consider excluding female mice from testing to avoid unpredictable noise that they believe can obfuscate clear conclusions. Daisya 35 year-old Harvard PhD who is fast becoming a Millennial firebrand on the topic of womens health in TEDx and other talkskept her cool so as not to be labeled difficult, something that women in scienceor any disciplinehave to always be aware of, she said. Taking a deep breath on the Zoom call, she suggested as calmly as possible that including female physiology is critical to developing any therapeutic to be used for a general population.

Dr. James Peyer, founder and CEO, Cambrian Biopharma

In the Spring of 2020 Daisy joined Cambrian Biopharma, which is developing therapeutics to combat the diseases of aging like cancer, heart disease, and Alzheimers disease. She convinced Cambrian co-founder and CEO James Peyer, a biologist and former venture capitalist, to add the aging of ovaries to his companys roster. This led a few months later to the formation of a new company under the Cambrian umbrella co-founded by Daisy called Oviva Therapeutics, powered by $11.5 million in seed fundinga big number for a just-hatched company.

The focus of Daisys company emerged out of her concern and curiosity about her own fertility. In 2018, at age 31, she began to wonder about her own prospects for having children in the futuresince kids now seemed a ways offshe began a deep-dive into issues of fertility. This included what was known, and not known, about the ovaries. I discovered that the ovaries are the first organ that really goes kaput, she said, leading to an accelerated decline in health for womenaffecting bone density, cardiovascular health, sexual function, metabolism, and on and on.

Overall, she noted, cellular aging accelerates an average of six percent after women reach menopause, typically beginning at age 52. And yet we have not put a lot of funding or effort into studying and understanding what this means for our health or how to create solutions to improve the negative consequences, she said.

Teaming up with Harvard molecular biologist and reproductive biology expert David Ppin, Daisy learned that a hormone produced by the ovaries called Anti-Mullerian Hormone (AMH) might be used to extend the functional life of the ovaries. Normally, AMH is used in IVF to measure the fertility of a patient. Ppin was experimenting with it to see if it would slow the progression of ovarian cancer.

Thats when he noticed that flooding ovaries with AMH also suppresses a process known as folliculogenesis. This is a process where some of the immatureor primordial folliclesare recruited for maturation, explained Daisy. Each month of an adult womans reproductive cycle, a group of roughly 1,000 follicles will mature, ultimately leading to ovulation of a single egg from just one follicle, the dominant follicle. The remaining follicles then die and wither away. This process eventually leads to a depletion of most of a womans follicles and the subsequent triggering of menopause. Using AMH to limit folliculogenesis preserves the possibility in the future that the follicles which women are born with and slowly lose over time do not get fully depleted, said Daisy.

We stumbled on this accidently, said Ppin. The result astonished us. When we added AMH, almost all of the immature follicles stopped growing, meaning the ovulation process largely froze in place, thus preserving the ovaries ability to produce mature eggs at a later date.

Harvard pediatric surgeon Patricia Donohoe, one of the great pioneers of reproductive medicine, also has worked closely with Ppin and is a co-founder and key advisor to Oviva and to Daisy. Ppin and Donoahoe developed a bio-engineered version of the naturally occurring AMH hormone. Pre-clinical data indicate that this bio-engineered AMH can protect the immature follicles during chemotherapy treatment, and potentially be used to improve IVF protocols by increasing the yield of viable eggs by 2-3x, a huge deal for women over the age 35.

The bioengineered form of AMH remains experimental, with the company running pre-clinical trials in mice and non-human primates. It is possible this will not succeed, said Daisy, most drug candidates dont, even those that reach human clinical trials. If this happens, she added, Oviva is poised to pivot to develop alternative treatments that would extend ovarian function and ultimately female healthspan.

Im excited about getting support and funding for studying the ovaries, said Daisy. Its a watershed moment in the history of womens health. She also welcomes others to join in.

To understand this field a bit better, I recently chatted about this topic with Daisy.

1. Female reproductive longevity and inequality seem to be a very hot topic. Why now? In your opinion, what triggered this sudden interest from the VCs?

Dr. Daisy Robinton, founder and CEO, Oviva Therapeutics

There has been a growing wave of interest in womens health over the last few years. In some ways COVID highlighted this in a somewhat backwards way. Early on there were statistics suggesting that more men were dying from COVID19 infection than women. This spurred an influx of funding to study female physiology to better understand why and potentially leverage these mechanisms to help men. Because we have historically overlooked females in biomedical research and clinical development, there is so much we dont know.

I think women are being more vocal about their needs, and an increase of women in power or positions of authority to help drive this change. And - there has also been a growing recognition that women have a lot of economic power behind them and the market for womens health is huge. Menopause alone has a market size of 14.7 billion and is growing. The US fertility market alone is $8 billion. And this doesnt even touch the various indications women suffer from that have little to no resources - things that I know patients would pay an arm and a leg to feel better from (endometriosis, PCOS, etc).

And then theres Roe v Wade, which of course is more immediate but brings into stark urgency the threat to womens health, reproductive freedoms and agency. This is a flashpoint and I am both furious and passionate about helping drive change so that females have more opportunities to live healthy, vibrant, resilient lives, so that we can feel and experience agency throughout our lives no matter our age.

2. Can you shine some light on how Oviva approaches the ovarian longevity challenge?

Our fundamental hypothesis is that ovarian function is inherently linked to healthspan, and by preserving or extending ovarian function we will also extend healthspan. Our first hypothesis that we are working on to address this is that through protecting or preserving the ovarian reserve - and therefore not depleting the ovarian reserve which ultimately triggers menopause and ovarian decline will prevent the ovaries from declining in function. Without the signal from a depleted ovarian reserve to shut down, the ovaries will believe that they should keep working rather than senescing and triggering menopause. The AMH/AMHR2 axis is the earliest known point where we can influence this AMH works by preventing immature (or primordial) follicles, each housing a single egg, from leaving the ovarian reserve. By leveraging this mechanism we aim to prevent the attrition of eggs (and primordial follicles) and thus preserve the ovarian reserve.

3. You share some investors with Gameto, can you please expand on how you are different?

Cambrian is our sole investor we are approaching this goal through the lens of longevity and with the hypothesis that extending ovarian function will significantly impact female health. Additionally, we are developing a candidate targeting the AMH/AMR2 axis which has yet to have any clinical development around it to date and are taking a very focused approach to this. The mechanism is fundamentally different from what Gameto is doing (cellular reprogramming), though the goals are similar. Frankly I think this is actually very important - ultimately what will serve women and patients best is having options to choose from. Much like birth control, different people will want or need distinct methodologies/therapeutics to support their health, so I am thrilled that we have a growing field working towards this goal of ovarian longevity. Gameto is working to reconstitute the ovaries, whereas we are looking to support and preserve the endogenous ovaries.

Also, we decided early on to develop a focused, rigorous program that was built out to thoughtfully de-risk as much as possible and to take us to clinic efficiently and effectively. We are initiating talks with the FDA this year, and this seed funding will take this program to IND submission. We have additional programs in early stages of development (more on that later this year will be tied to our Series A), but we felt strongly that we want to devote our attention to this first program and indication in order to drive it forward effectively without diluting our attention across multiple assets to start. We believe this allows us to take a deeper, more rigorous approach to what we are doing and build from a strong foundation. This focused approach sets us apart from other companies in the space that share our mission and who I hope succeed! and who are working on several things simultaneously. For us this seed round and focused approach - we believe - is the most effective strategy to get to clinic and be successful. Related to this, our candidate is closest to clinic and we are excited to test in humans soon and determine whether this has the potential for our broader vision of extending ovarian function - but one step at a time.

4. What do you see as the major obstacles to achieving ovarian longevity?

There are many fundamental questions about ovarian physiology - and womens health more broadly - that remain unanswered. In order to make a positive impact on ovarian biology we also have to understand the consequences of extending ovarian function (positive and negative) to ensure what were doing is safe in humans and achieving the desired goal, which is ultimately to provide therapeutic options to women that preserve agency over their bodies and reproductive health.

5. In the pharmaceutical industry we usually go after specific diseases. And in longevity biotechnology, most companies try to go after dual-purpose targets that may work in aging and disease. What indications are you targeting?

For our first program we are targeting poor responders to IVF. Similar to the longevity field we view this as an important stepping stone to advance our broader goal of prolonging ovarian function and forestalling the negative consequences that occur as the ovaries decline with age. This first indication (and those to follow, currently confidential) will enable us to establish safety and efficacy (evaluating efficacy and function in humans).

Oviva is one of 19 offspring companies tucked into the Cambrian fold that address certain system-wide triggers of aging. These include using stem cells to regenerate damaged or aging tissue; a treatment that counters the effects of those dwindling telomeres; and yet another that inhibits the formation of fibrotic cells that thicken and cause damage to the lung, uterus and other organs. To learn about longevity biotechnology, Cambrian biosciences, and many other cutting-edge academic and industry projects, consider registering for the 9th annual Aging Research and Drug Discovery conference, 29.08-2.09 in Denmark, hosted by the University of Copenhagen.

The rest is here:
Can We Fix Ovarian Aging? Here Is One Startup Up For The Task! - Forbes

Gut health is vital for one's overall health and quality of life. A new study has shown how it can also directly impact brain and eye function, and boost your longevity

Image: Getty Images)

Eating a healthy, balanced diet is an important part of maintaining good health and helping you feel your best.

The gut microbiota, the body's largest population of microorganisms, are increasingly recognised as an important regulator of host immunity and brain health.

All food is ultimately broken down in the gut to a simple form that can enter the bloodstream and be delivered as nutrients throughout our bodies. This is only possible with a healthy digestive system.

A healthy gut contains healthy bacteria and immune cells that ward off infectious agents like bacteria, viruses and fungi.

A healthy gut also communicates with the brain through nerves and hormones, which helps maintain general health and well-being.

Image:

They can be found in the intestine, and a new study has found they they play a vital role in regulating some of the detrimental effects of ageing, meaning it could be a key to living longer.

It has been known for some time that the population of microbes that we carry around in our gut, collectively called the gut microbiota, is linked to overall health.

From inflammatory bowel diseases, cardiovascular, autoimmune, metabolic and neurodegenerative disorders; our gut microbiome could be the determining factor for disease reduction and longevity.

In a new study, faecal transplants in mice showed a reverse of some of the effects of ageing in both the retina and the brain.

Researchers exchanged the gut microbes among three groups of mice: three months old, designed as "young," 18 months old, designated as "old," and 24 months old mice, classified at "aged." A mouse that is two years old is equivalent to a human who is between 70 and 80 years old.

They then analysed the changes in gut composition to better understand how faecal transplantation affected inflammation on the gut barrier, retina of the eye and the brain, which decline with age partly due to chronic inflammation.

Researchers found transferring "faecal slurries" from aged donors to young mice led to a weakening of the gut lining, which allowed bacterial products to enter the circulation, triggering an inflammatory response in the brain and eyes.

However, the harmful effects were shown to be be reversed by faecal transplants from the young donor mice into older mice.

The team also found specific proteins associated with retinal degeneration were elevated in the young mice who received a faecal transplant from the old donors, further bolstering the claims of how ones gut microbiome can affect longevity.

"Our data support the suggestion that altered gut microbiota in old age contributes to intestinal and systemic inflammation, and so may contribute to driving inflammatory pathologies of aged organs," wrote the study authors.

Image:

Professor Simon Carding, from UEA's Norwich Medical School and head of the Gut Microbes and Health Research Programme at the Quadram Institute, added: "This ground-breaking study provides tantalising evidence for the direct involvement of gut microbes in ageing and the functional decline of brain function and vision and offers a potential solution in the form of gut microbe replacement therapy."

Ways to improve your gut health include:

Read More

Read More

Go here to read the rest:
Boost longevity: Healthy gut can improve brain function and increase lifespan - new study - The Mirror

Milo Bryant is a performance coach as well as an experienced journalist. Hes also in his 50sand his book Unstoppable After 40 gives you the roadmap to do more than merely remain active as you "mature." Milo trains hard and recovers even better so he can do what he wants, when he wants. Get ready to use his methods to become unstoppable. This isnt your dads middle age.

The following is an excerpt from Unstoppable After 40.

Movement. Matters.

We have to make more time for movement. And specifically, we need to relearn how to move. Movement is more vital to our health and well-being than any other factor besides good nutrition. Not just practicing but perfecting movement puts the life in living.

Does that sound fanatical? Well, call me converted. I am a faithful, devoted follower of what I like to call the First Church of Human Movement. Its Word is sound and powerful. Bending, extending, squatting, twisting, balancingthis, folks, is what will keep us healthy for the next 40 years.

Im what many might stereotype as a functional fitness trainer. What I do, though, is all about performance, no matter the activity. I do whatever it takes to help athletes move and perform better. If that means Olympic lifts, I teach the clean-and-jerk and the snatch and all the exercises that go along with those. If that means sprinting, the athletes will find themselves repeating everything from figure-4 cycles to over-speed hurdle hops.

Folks, Ive done plenty of cave work and participated in more than my share of National Bench and Triceps Days. All of thatthe benching, squats, and deadliftsare great. But theres nothing I do or want to do that requires me to push weight up from my chest (there was actually a two-decade span, from 1999 to 2019, where I didnt bench press) or put ungodly amounts of stress on my back.

Men's Health

Unstoppable After 40 - Men's Health Shop

$24.95

I still deadlift (mostly with a trap bar) because that lift checks a lot of functional boxes. The older Ive gotten, the smarter Ive become about my training. You dont have to prove anything to the youngsters at the gym. You just need to be ready to play.

Im training to kite surf in Tarifa, hike Mount Kilimanjaro, and learn Bachata and Kizomba. After all, why would we train to be in the best possible shape if not to increase the joy in life?

You might think the key to never slowing down is to maintain as much muscle as possible. But that power will fizzle if youre easily injured. Bulletproof your body by focusing on movements in two key categories: mobility and stability.

Your body needs to move every day in order to keep working the right way. But over the course of four-plus decades, youve likely limited your daily movement to just a handful of positions. Ignoring all other potential ways your body can move leaves you susceptible to injury. Thats where mobility exercises come in handy.

Mobility is a joints ability to move freely through its full range of motion without pain. Exercises like the Spiderman Lunge or Superman Hold can help you preserve ease of movement. Theyll lubricate tight hips, relax your back, and stave off neck pains, too. Best of all, they dont take long to do. Want more mobility movements? Check out this 30-day challenge.

Stability is your foundation. Its your ability to remain balanced. We all learned it as a kid, but it requires upkeep as we get older. Research shows that stability training can significantly reduce your risk of injury, plus it makes building strength a lot easier. The less stable you are, the less force youll be able to produce.

Stability moves, like the series of lunges youll learn in Unstoppable After 40, challenge your balance and help you remain anchored as you move through daily life. Work these into your regular routine and youll be unshakeable.

This content is created and maintained by a third party, and imported onto this page to help users provide their email addresses. You may be able to find more information about this and similar content at piano.io

View original post here:
The 2 Types of Workout Movements Men Over 40 Need for Longevity - Men's Health

Up today is Fitbiomics, which spun out of Harvard several years ago with a mission to decode and recode human health, starting by mining the microbiomes of elite athletes for novel probiotic candidates.

We caught up with Jonathan Scheiman, PhD, co-founder and CEO, who gave us his thoughts on his path to market, the lessons learned launching a consumer brand during a pandemic, and whats coming next in the Fitbiomics pipeline.

NutraIngredients-USA (NIU): Tell us how you went from the Wyss Institute to being CEO of a probiotics start-up

Jonathan Scheiman (JS): I was incredibly lucky to do a postdoctoral fellowship at the Wyss Institute for Biologically Inspired Engineering. The mantra there is to translate cutting-edge research into real-world applications that can benefit society in numerous ways, from human to environmental health. The Wyss is focused on bringing innovations out of the lab to serve as a foundation for transformative startups - and that sort of environment greatly fosters entrepreneurship. We spent years developing our microbiome R&D as an academic project, which led to a high-impact publication and IP. But in parallel there was a tremendous amount of market research and business development coaching that enabled us to ascertain how our technology could be commercially viable. Ultimately - FitBiomics licensed IP that was developed at the Wyss which was such a springboard for our company. Also, based on our origins within biotechnology and metagenomics it informed our foundation and viewpoint for who we want to be as a company. I'll just say that FitBiomics is not necessarily a probiotics company. We view ourselves as a next gen human health and performance company, using microbiome Innovations as a force for good to change human health and longevity as we know it

(NIU: To read more about the Fitbiomics origin story, please click HERE)

NIU: How would you say your approach or ethos is treading a path or direction that no other firm company has explored before?

JS: A big differentiation point for FitBiomcis is our guiding principle of decoding and recoding human health. I am a big believer in form fits function and natural selection - finding solutions through evolution. So if we want to develop next-gen probiotics for human health - we believe the best place to search for that is in the biology of the most fit and healthy people in the world. Thus FitBiomics is decoding the gut microbiome of elite phenotypes to identify what is unique or enriched in them, that drives optimal performance, and then translate those findings into next gen nutrition to help every body. There are many forms of elite phenotypes, with many beneficial types of physiology we can decode - from energy metabolism, protein metabolism, neurology, and an immunology perspective. We are focusing to start on elite athletes and looking for microbes enriched in them that help drive endurance, strength, mental toughness, and recovery. Though these attributes clearly extend beyond athletics finding probiotics that support these functions can help everyone int their daily lives.

NIU: You launched Nella during a pandemic how has that experience been and whats the initial feedback been like from the market?

JS: It definitely is an interesting time - for the whole world, which has changed the way we live in many ways. We actually started our first beta test for Nella in March 2020, right before everything shut down in the States. I guess one positive is that people have become more conscientious about their health and what they are putting in their bodies. This is across the board, and includes sustainability interests, but certainly part of this is that probiotics and gut health have become even more mainstream even just the term microbiome.

FitBiomics is always hypothesis and validation driven - so our beta test was with 250 participants, each consuming Nella on a daily basis for 2 weeks and asking for feedback through extensive questionnaires before, during, and after consumption. I remember us thinking that if at least 70% of the participants indicated they liked our product, then we should consider moving forward with commercialization. As it turned out almost 95% of participants responded they had at least one functional benefit from Nella - in only two weeks! These benefits included improved digestion, bowel movements, energy as well as improved quality of sleep. Because Nella consists of athlete derived variants of Lactobacillus species, we somewhat expected the gut health results, but the feed ack on benefits for sleep was very exciting. This propelled us to move forward, and we launched Nella direct-to-consumer a little over a year ago. We have since received tremendous positive feedback and insights from the market. I like to say that we have been field tested as well - with Olympians using Nella in Tokyo to win medals. Additionally, weve had world champions and world record holders use Nella to support their pursuits - so even super performers are benefiting.

We have also partnered with St. Johns University to be the official probiotic of the University, while supporting student-athletes with microbiome innovations and NIL. Which of course was a treat for me because that's where I played basketball in college. Even more exciting - we recently had some really great news coverage in the NY Post and on Good Day New York. The headlines were a little provocative - but ultimately about health, which created a viral demand for Nella - to the point where we recently sold out of stock! So Id say that it's been an incredible journey of translating initial discoveries from Harvard into the real world products that have been validated and generated strong Market interest. But perhaps more importantly Nella is providing strong functional benefits to a wide range of consumers - from everyday health seekers all the way to Olympians

NIU: What else is in the pipeline (that you can tell us about)?

JS: This is such an appreciated question - because there is a lot in the pipeline! FitBiomics first gained attention for our discovery of Veillonella, a lactic acid eating microbe, and subsequent publication in Nature Medicine. We found that Veillonella increases in abundance in the gut of elite athletes after exercise and has the unique ability to convert lactic acid, a by-product of exercise and associated with fatigue, into short-chain fatty acids to promote endurance in preclinical studies. Since that publication Im excited to say we have upscaled Veillonella manufacturing - creating commercially viable prototypes (no small feat for a next-gen anaerobic probiotic) and have passed the necessary safety studies required from a regulatory standpoint. So, we have effectively gone from a lab scale discovery to a real-world product and its awesome to see it come to fruition being close to commercial ready, We have some announcements that well be making shortly so stay tuned! But beyond gut health with Nella and endurance with Veillonella, our Endgame is to scale our microbiome discovery platform isolating 1000s of next-gen probiotics, from a spectrum of elite phenotypes, for numerous functional applications. This includes programs for strength, neurological applications, and more. And of course, there are opportunities for utilizing some of these microbes for applications beyond consumer health. so, it's an exciting time for microbiome discovery and translation

NIU: Access to capital is always an issue for start-ups. Does being in the microbiome space change the conversation with potential investors?

JS: Being an entrepreneur is always an adventure and part of our job is trying to not only see the future but convince others that 1) our venture is a worthwhile endeavor 2) its feasible to accomplish our aspirational goals and then of course 3) that you can create a sustainable business model at the same time! I do think there is an interesting juncture right now between biotechnology, microbiome innovations, and a new wave of food tech. Biotech and the microbiome traditionally have been focused on therapeutics, but I think a lot of folks now see how these areas can be applied to nutritional modalities for health and wellness purposes. So, in addition to treating disease also focusing on prevention - with sort of a food as medicine approach. With FitBiomics, we like to add the exercise as medicine approach as well - keeping people active keeps people healthy. And this created a lot of excitement for investors.

There is also a lot of very real and alarming data out there from the CDC in that 60% of Americans have at least one chronic condition (obesity, diabetes, kidney, cardiovascular, neurological) a lot stemming from poor nutrition and lack of physical activity. So, innovation in consumer health is not just a nice to have its critical I think a lot of people believe in the microbiome and the probiotics industry is strong and continues to grow. With that said, it's very interesting times in the world and I think more people are looking for de-risking early on with ventures. So, it's a combination of storytelling, in which the microbiome helps, but also there is a requisite for innovation, IP, and at the same time validating market demand and business models. FitBiomics, as a lean startup, has been trying to accomplish all of these things in unison since spinning out of Harvard around 4 years ago

NIU: In the probiotic, prebiotic and microbiome space, what would you say is the next research area that the industry needs to keep its eye on?

JS: I think in general it's an exciting time because we're just scratching the surface of a new frontier in human health with biotechnology and multi-omics leading the way. I definitely think the industry needs to focus on diversity, acceleration, and accessibility. When you think about the probiotics industry - its decades-old with only a handful of strains on the market, from a handful of suppliers and manufacturers. Many of these strains were isolated from food, baby poop, animals, or the environment - mostly selected because of their ability to be manufactured at scale. For sure, a Lot of work has gone into developing this industry. But contrast that with the trillions of microbes in our bodies and environment afforded to use from natural diversity and evolution. We need to continue to decode diverse forms of health which could be associated with exercise, aging, resiliency, food tolerance, and efficacy of therapeutic use, to name a few. Learnings from such endeavors and source codes can lead to applications in animal and planetary health as well and the more we learn the more precision based our probiotic modalities will become. And we of course to need to continue the evolve metagenomics, informatics, culturomics, and fermentation pipelines to accelerate discovery and scalability of next-gen (anaerobic) microorganisms.

Perhaps most important we need to educate consumers about the importance of this work, biotechnology, the microbiome, gut health, and probiotics. We also need to translate and optimize our supply chains to make innovations are accessible and affordable to broader populations, so that that that ensuring everyone can benefit from innovations in health. Fitbiomics looks to achieve this by bridging the gap between cutting edge technology and pop culture - creating awareness aroundmicrobiome innovations while making them more relevant and tangible.

NIU: Finally, what is the significance for Fitbiomics of being named one of our 2022 Probiota Pioneers, and how do you think it helps your profile in such an innovative, ever-changing industry?

JS: This is such an honor! It truly is exciting to be a part of this community and recognized as a Probiota Pioneer. It's also in many ways validating. Being an entrepreneur inherently means being avant-garde, thinking differently, and essentially trying to convince people you're not crazy. Were effectively trying to build the future in real time but that can take a long time. I think back to starting our first athlete microbiome study at Harvard in 2015 and here we are 7 years later. Maybe what we were doing was considered niche and/or a crazy concept but perhaps the craziest thing is that a lot of it came to fruition. And I feel like the Probiota community has sort of watched us grow up along the way. So, I think the significance is a way of saying that the journey was/is worth it. It keeps us motivated to explore and innovate and push the boundaries of what we think is possible. This sort of validation, support, and recognition from the industry is something that means the world and inspires us to continue to think differently.

The2022 IPA World Congress + Probiota Americas, June 1-3 in Washington, D.C., will feature world-leading experts to present the latest scientific, technical and market insights, and opens with presentations about the potential impact of probiotics on COVID-19 outcomes. Other key themes include: e-commerce markets across the Americas; Microbiome modulation to improve sleep and manage stress, the Tech Showcase; updates from the regulatory field, tips and tricks on working with influencers to communicate with consumers, insights from leading start-ups, and our Future Focus panel, which asks Where Next for the Industry?

For more information and to register, please clickHERE.

See original here:
Probiota Pioneers: Fitbiomics on its product pipeline and the goal to scale its microbiome discovery platform - NutraIngredients-usa.com

"From a historical perspective, we are at an inflection point in biosciences where we can advance people's well-being to unprecedented levels. To achieve such levels, a two pronged approach is crucial," says Baran Dilaver, Co-Founder of Wonderfeel. "The first approach is to leverage recent discoveries to build our physiological health starting at the molecular level, and the second is by enhancing our happiness and mental fitness. Youngr is a breakthrough product addressing that anatomical approach while providing great benefits for brain health and cognition."

Longevity science is an emerging category poised to redefine the future of preventive healthcare. Scientists focused on optimizing healthspan the period of life spent in good health and free from chronic disease have proven that NAD plays a central role. The effects of its decline are recognized as the hallmarks of aging. With the launch of Youngr, Wonderfeel has advanced that science for those who will benefit most adults ages 35+.

Youngr NMN (nicotinamide mononucleotide) capsules deliver novel antioxidants for a multi-targeted approach designed to reduce oxidative stress, help prevent chronic disease, and stave off markers of aging. In addition to 900 mg of NMN, a daily serving delivers:

Andrew Salzman, Harvard MD and Wonderfeel's chief scientist, piloted the core research behind Youngr. A physician, inventor, and biomedical entrepreneur, Salzman has spent decades in drug discovery and development. In addition to 50 patents, Dr. Salzman is credited with a breakthrough discovery in cellular DNA repair, which led to the world's first clinical application for successfully treating breast cancer caused by mutations in BRCA1 and BRCA2 genes, and is an expert in NAD science and genomic pathways.

"NMN alone is incredibly beneficial. But the ability of NMN and NAD to be effective in the cell is dependent on low oxidative stress," explains Dr. Andrew Salzman. "Oxidant stress is present at all times in our cells, particularly as we grow older. Fortunately, the antioxidants packaged into Youngr can shield our cells from much of that stress, meaning the NMN we're delivering is ultimately more effective."

Wonderfeel partnered with Abinopharm, Inc, to analyze, interpret and release their preliminary findings from the largest double blind study conducted to date on the effects of NMN. According to Dr. Salzman, the results are promising, with men and women aged 40-65 who took various doses of NMN supplement showing significantly improved health scores and biomarkers.

For more information about Youngr and product news, visit: http://www.getwonderfeel.com

About Wonderfeel By combining the wonders of nature and science, Wonderfeel is on a mission to optimize the healthspan of humankind. Founded in Silicon Valley in 2018, Wonderfeel is a team of pioneering doctors, creators, entrepreneurs, and scientists, who set out to accelerate wellness technologies through bioscience. Their products leverage the magic of the body's own regenerative systems, empowering individuals with safe solutions to help them live long, healthy lives.

SOURCE Wonderfeel

See the rest here:
Wonderfeel to Launch Youngr, Targeting the Root Causes of Aging - PR Newswire

Spotted

07:30

by Mary Harrington

In case intergenerational solidarity wasnt bad enough, news arrived this week that scientists have discovered yet more ways to help the elderly by cannibalising the young.

Researchers have discovered that infusing the cerebrospinal fluid of young mice into older mice improved brain function, which according to Dr Tony Wyss-Coray of Stanfords School of Medicine in California, suggests that the ageing process is malleable. Previous research seems to suggest that blood transfusions from the young to the old have a rejuvenating effect, too.

How long until someone tries to apply this to humans? With the youngest boomers approaching 60, theyre now collectively confronting their own mortality. As such, this cohort is the most obvious demographic to drive demand, economically as much as culturally: theyre wealthier than subsequent generations, and also saw the swiftest decline in religious faith.

Boomer ageing, then, is a perfect storm: a taboo-smashing demographic, often lacking the kind of religious framework that would encourage acceptance of mortality and, in aggregate, the money to fight back. Indeed, while theres no evidence hes cannibalising childrens body fluids, ultra-rich boomers such as Jeff Bezos now pour immense resources into seeking the secret of eternal life.

The spinal-fluid and blood-transfusion experiments were conducted with mice, and no one at present is suggesting harvesting body fluids from young humans in order to rejuvenate the elderly. But still, its not such a huge stretch to imagine that at least some of the generation that first embraced the phrase Nothing is true, everything is permitted might ask themselves: why shouldnt I?

A company offering transfusions of teenage blood plasma to wealthy Silicon Valley retirees was shut down in 2019 by the FDA only to start up again a few months later albeit with more evasive marketing materials and health claims. And if someone with a net worth of $182 billion wanted a supply of human infant cerebrospinal fluid, I dare say hed be able to get one.

Lets hope biotech dystopias of this kind remain science fiction. Even so, the scenario underlines an unsettling sense that seemingly abstract and objective scientific research into new biotech skates far too lightly over power asymmetries with potentially ghoulish consequences.

Its quite possible that the vast majority of the baby-boomer generation, and indeed those that come after, would balk at literally cannibalising the young in pursuit of eternal youth. But so far the 21st century is delivering an unsettling combination of widening economic inequality and advances in biotech that leave the door wide open for horrifying new kinds of exploitation: the killing to order of Chinese political prisoners for the organ transplant industry is just one glimmer of where this could go.

Meanwhile, were losing any sense of a shared moral framework that might be able to hold such developments in check. Elon Musk, for one, thinks were all already cyborgs. Those comforting themselves with the thought that we have bioethicists to help us think through the moral consequences of such research, might want to check in with the kind of things bioethicists say. Brace yourselves: biotech is going to deliver the mother of all culture wars.

Go here to see the original:
Beware millennials, boomers want your blood - The Post - UnHerd